American Journal of Obstetrics & Gynecology
Volume 199, Issue 6, Supplement B , Pages S367-S372, December 2008

The clinical content of preconception care: the use of medications and supplements among women of reproductive age

  • Anne L. Dunlop, MD, MPH

      Affiliations

    • Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, GA
  • ,
  • Paula M. Gardiner, MD, MPH

      Affiliations

    • Department of Family Medicine, Boston University Medical Center, Boston, MA
  • ,
  • Cynthia S. Shellhaas, MD, MPH

      Affiliations

    • Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine and Director for Bureau of Child and Family Health Services, State of Ohio, OH
  • ,
  • M. Kathryn Menard, MD, MPH

      Affiliations

    • Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC
  • ,
  • Melissa A. McDiarmid, MD, MPH

      Affiliations

    • University of Maryland, Occupational Health Program, Baltimore, MD

Received 17 June 2008; accepted 29 July 2008.

The use of prescription and over-the-counter medications and dietary supplements are common among women of reproductive age. For medications, little information about the teratogenic risks or safety is available, as pregnant women are traditionally excluded from clinical trials, and premarketing animal studies do not necessarily predict the effects of treatment in human pregnancy. Even less is typically known about the effects of dietary supplements on pregnancy outcomes, as they are not held to the same rigorous safety and efficacy standards as prescription medications. Congenital anomalies associated with medication use are potentially preventable, because they are linked with modifiable maternal exposures during the period of organogenesis. However, as women of reproductive age experience acute and chronic conditions that can result in adverse outcomes for the woman and her offspring, the benefits of use of a particular medication before or early in pregnancy may outweigh the risks. Resources and principles outlined in this article will aid healthcare providers in selecting appropriate medication regimens for women of reproductive age, particularly those with chronic health conditions, those who are planning a pregnancy, and those who may become pregnant.

Key words: medication, preconception, prescription, teratogen

 

 Reprints not available from the authors.

 Conflict of Interest: Anne L. Dunlop, MD, MPH; Paula M. Gardiner, MD, MPH; Cynthia S. Shellhaas, MD, MPH; M. Kathryn Menard, MD, MPH; and Melissa A. McDiarmid, MD, MPH have no conflict of interest including grants, honoraria, advisory board membership, or share holdings.

PII: S0002-9378(08)00885-5

doi:10.1016/j.ajog.2008.07.065

American Journal of Obstetrics & Gynecology
Volume 199, Issue 6, Supplement B , Pages S367-S372, December 2008